Oncology Associates of Oregon

Eugene, OR

Sorting 3 by

Accepting patients

SGR-2921

A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
  • CDC7 Inhibitor
  • Phase 1

Not yet accepting

PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
  • IDH1 Inhibitor
  • Randomization
  • Phase 3

Accepting patients

AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
  • Monoclonal Antibody
  • CD47
  • Closed Label (Masked)
  • Placebo
  • Randomization
  • Phase 2